
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1946371/publications.pdf Version: 2024-02-01



ΙΟςΗΠΑ Μ ΤΗΠΡΜΑΝ

#	Article	IF	CITATIONS
1	A clinical approach to children with C3 glomerulopathy. Pediatric Nephrology, 2022, 37, 521-535.	1.7	9
2	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
3	Elevated Detection of Dual Antibody B Cells Identifies Lupus Patients With B Cell-Reactive VH4-34 Autoantibodies. Frontiers in Immunology, 2022, 13, 795209.	4.8	4
4	Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science, 2022, 375, eabf7470.	12.6	36
5	Minimal Change Disease Is Associated With Endothelial Glycocalyx Degradation and Endothelial Activation. Kidney International Reports, 2022, 7, 797-809.	0.8	11
6	Rhabdomyolysis and complement—once again, epithelial cells take center stage. Kidney International, 2021, 99, 537-539.	5.2	2
7	BLISS in the Treatment of Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 969-971.	4.5	2
8	Mechanisms of SARSâ€CoVâ€2â€induced lung vascular disease: potential role of complement. Pulmonary Circulation, 2021, 11, 1-14.	1.7	34
9	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. American Journal of Physiology - Renal Physiology, 2021, 321, F505-F516.	2.7	16
10	Complement Detection in Mouse Kidneys by Immunofluorescence. Methods in Molecular Biology, 2021, 2227, 179-189.	0.9	0
11	Complement Activation Fragments Are Increased in Critically III Pediatric Patients with Severe AKI. Kidney360, 2021, 2, 1884-1891.	2.1	5
12	Complement fragments are biomarkers of antibody-mediated endothelial injury. Molecular Immunology, 2020, 118, 142-152.	2.2	10
13	Complement and Cancer—A Dysfunctional Relationship?. Antibodies, 2020, 9, 61.	2.5	10
14	Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Frontiers in Immunology, 2020, 11, 1460.	4.8	14
15	Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. Journal of Experimental Medicine, 2020, 217, .	8.5	40
16	Complement-mediated kidney diseases. Molecular Immunology, 2020, 128, 175-187.	2.2	31
17	Complement and the Kidney: An Overview. Advances in Chronic Kidney Disease, 2020, 27, 86-94.	1.4	26
18	Complement factor H–deficient mice develop spontaneous hepatic tumors. Journal of Clinical Investigation, 2020, 130, 4039-4054.	8.2	30

#	Article	IF	CITATIONS
19	Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?. Global Cardiology Science & Practice, 2020, 2020, e202001.	0.4	17
20	SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb. Molecular Imaging and Biology, 2019, 21, 473-481.	2.6	19
21	Urine complement activation fragments are increased in patients with kidney injury after cardiac surgery. American Journal of Physiology - Renal Physiology, 2019, 317, F650-F657.	2.7	12
22	The Role of Complement in Organ Transplantation. Frontiers in Immunology, 2019, 10, 2380.	4.8	43
23	Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress. American Journal of Physiology - Renal Physiology, 2019, 317, F683-F694.	2.7	12
24	The role of complement in antibody mediated transplant rejection. Molecular Immunology, 2019, 112, 240-246.	2.2	22
25	Complement Therapeutics in Autoimmune Disease. Frontiers in Immunology, 2019, 10, 672.	4.8	46
26	Targeting the Immune Complex–Bound Complement C3d Ligand as a Novel Therapy for Lupus. Journal of Immunology, 2019, 203, 3136-3147.	0.8	15
27	A Patient with Hemolytic Uremic Syndrome and Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 933-936.	4.5	1
28	Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. European Journal of Immunology, 2018, 48, 791-802.	2.9	17
29	Modulation of the Alternative Pathway of Complement by Murine Factor H–Related Proteins. Journal of Immunology, 2018, 200, 316-326.	0.8	14
30	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Research, 2018, 78, 143-156.	0.9	94
31	Recent advances in renal imaging. F1000Research, 2018, 7, 1867.	1.6	22
32	Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Frontiers in Immunology, 2018, 9, 535.	4.8	29
33	Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy. Frontiers in Immunology, 2018, 9, 1433.	4.8	47
34	Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2018, 7, .	3.7	47
35	Getting over our Immune-Complex – C5a receptor blockade is the answer. Cellular and Molecular Immunology, 2017, 14, 319-320.	10.5	1
36	Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children. Pediatric Research, 2017, 81, 857-864.	2.3	102

#	Article	IF	CITATIONS
37	Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrology Dialysis Transplantation, 2017, 32, i57-i64.	0.7	13
38	Complement factor H–related proteins in IgA nephropathy—sometimes a gentle nudge does the trick. Kidney International, 2017, 92, 790-793.	5.2	7
39	Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS ONE, 2016, 11, e0166200.	2.5	23
40	Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney International, 2016, 90, 109-122.	5.2	16
41	Never make assumptions: theÂcomplicated role of complement in urinary tractÂinfections. Kidney International, 2016, 90, 469-471.	5.2	4
42	All Things Complement. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1856-1866.	4.5	61
43	Targeting the complement cascade: novel treatments coming down the pike. Kidney International, 2016, 90, 746-752.	5.2	41
44	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. Journal of Immunology, 2016, 196, 4671-4680.	0.8	35
45	New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Seminars in Immunology, 2016, 28, 260-267.	5.6	20
46	Annexin A2 Enhances Complement Activation by Inhibiting Factor H. Journal of Immunology, 2016, 196, 1355-1365.	0.8	16
47	Î ³ δT cells protect against LPS-induced lung injury. Journal of Leukocyte Biology, 2016, 99, 373-386.	3.3	12
48	The Complement System and Antibody-Mediated Transplant Rejection. Journal of Immunology, 2015, 195, 5525-5531.	0.8	67
49	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	8.2	65
50	A high-performance liquid chromatography – tandem mass spectrometry – based targeted metabolomics kidney dysfunction marker panel in human urine. Clinica Chimica Acta, 2015, 446, 43-53.	1.1	28
51	IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney International, 2015, 88, 528-537.	5.2	41
52	Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research, 2015, 4, 153.	1.6	7
53	Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS ONE, 2015, 10, e0136558.	2.5	54
54	Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research, 2015, 4, 153.	1.6	3

#	Article	IF	CITATIONS
55	Deletion of the Complement C5a Receptor Alleviates the Severity of Acute Pneumococcal Otitis Media following Influenza A Virus Infection in Mice. PLoS ONE, 2014, 9, e95160.	2.5	18
56	Detection of complement activation using monoclonal antibodies against C3d. Journal of Clinical Investigation, 2013, 123, 2218-2230.	8.2	78
57	Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. American Journal of Physiology - Renal Physiology, 2012, 302, F1529-F1536.	2.7	10
58	Molecular Imaging of Autoimmune Diseases and Inflammation. Molecular Imaging, 2012, 11, 7290.2011.00045.	1.4	14
59	The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. CKJ: Clinical Kidney Journal, 2010, 3, 346-348.	2.9	3
60	The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. American Journal of Physiology - Renal Physiology, 2007, 293, F555-F564.	2.7	49
61	C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion. Journal of Immunology, 2007, 178, 1819-1828.	0.8	104
62	Treatment with an Inhibitory Monoclonal Antibody to Mouse Factor B Protects Mice from Induction of Apoptosis and Renal Ischemia/Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2006, 17, 707-715.	6.1	116
63	The Central Role of the Alternative Complement Pathway in Human Disease. Journal of Immunology, 2006, 176, 1305-1310.	0.8	386
64	Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. Journal of Clinical Investigation, 2006, 116, 357-368.	8.2	149
65	Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney International, 2005, 67, 524-530.	5.2	123
66	A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Molecular Immunology, 2005, 42, 87-97.	2.2	157
67	Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. American Journal of Medicine, 2003, 114, 588-598.	1.5	51